Cite
Shuster A, Pechalrieu D, Jackson CB, et al. Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein. ACS Chem Biol. 2021;16(12):2845-2851doi: 10.1021/acschembio.1c00756.
Shuster, A., Pechalrieu, D., Jackson, C. B., Abegg, D., Choe, H., & Adibekian, A. (2021). Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein. ACS chemical biology, 16(12), 2845-2851. https://doi.org/10.1021/acschembio.1c00756
Shuster, Anton, et al. "Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein." ACS chemical biology vol. 16,12 (2021): 2845-2851. doi: https://doi.org/10.1021/acschembio.1c00756
Shuster A, Pechalrieu D, Jackson CB, Abegg D, Choe H, Adibekian A. Clinical Antiviral Drug Arbidol Inhibits Infection by SARS-CoV-2 and Variants through Direct Binding to the Spike Protein. ACS Chem Biol. 2021 Dec 17;16(12):2845-2851. doi: 10.1021/acschembio.1c00756. Epub 2021 Nov 18. PMID: 34792325; PMCID: PMC8610013.
Copy
Download .nbib